<DOC>
	<DOCNO>NCT00243789</DOCNO>
	<brief_summary>The purpose study see male child Duchenne muscular dystrophy ( DMD ) change strength give drug Pentoxifylline rescue treatment . A total 64 subject expect participate center Cooperative International Neuromuscular Research Group ( CINRG ) worldwide . The primary purpose study see whether addition pentoxifylline steroid regimen effective treat deteriorate muscle strength compare muscle strength PTX treat subject placebo treat subject .</brief_summary>
	<brief_title>Study Daily Pentoxifylline Rescue Treatment Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>DMD common devastate type muscular dystrophy ( incidence 1 3500 live bear male worldwide ) . DMD characterize complete loss dystrophin , lead progressive muscle weakness waste . No cure currently available despite present understanding disorder discovery characterization causative gene protein product dystrophin 1987 . Corticosteroids ( prednisone , deflazacort ) may delay disease progression treatment prove beneficial patient DMD . Other alternative supplement like creatine glutamine also delay diseased progression .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>Male Age 7 year 100 year Ability ambulate 10 meter . Assistive device allow . Diagnosis DMD confirm least one follow : On stable dose prednisone , prednisolone deflazacort least 12 month prior screen . Participants stable dose combination follow compound ( creatine , glutamine , coenzyme Q10 , vitamin E , C D , JUVEN , arginine , calcium ) must take medication least 2 month prior screen . Subjects require take medication participate study . All herb , supplement green tea ( note ) discontinue 3 month prior screen . Ability provide reproducible QMT bicep score 15 % variation score screen . Normal blood clot ability evidence platelet function assessment ( PFA ) . Currently enrol another treatment clinical trial . History significant concomitant illness significant impairment renal hepatic function . History impairment blood clot ability ( evidence increase PT/PTT PFA upper limit normal ( ULN ) ) . Recent cerebral retinal hemorrhage . History bleed diathesis gastric ulcer .</criteria>
	<gender>Male</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Duchenne</keyword>
	<keyword>Genetic</keyword>
	<keyword>Muscular Dystrophy</keyword>
	<keyword>DMD</keyword>
</DOC>